Xpert® MTB/RIF for national tuberculosis programmes in low-income countries

When, where and how?

Arnaud Trébucq, D. A. Enarson, C. Y. Chiang, A. Van Deun, A. D. Harries, F. Boillot, A. Detjen, P. I. Fujiwara, S. M. Graham, I. Monedero, I. D. Rusen, H. L. Rieder

Research output: Contribution to journalArticle

91 Citations (Scopus)

Abstract

Xpert® MTB/RIF offers new and important possibilities for the diagnosis of sputum smear-negative tuberculosis (TB) and/or rifampicin (RMP) resistance, and many are encouraging rapid and widespread implementation. This simple test can be implemented almost everywhere, and it provides results within a few hours. In low-income countries (LICs), however, its cost, environmental limitations (stable and regular electricity, adequate room temperature) and difficulties involved in supply and maintenance are major obstacles. While it may be suitable for major reference hospitals, operational research is needed to evaluate the test and its additional yield above high-quality smear microscopy and clinical algorithms before its use at the peripheral level. In the meantime, direct microscopy should remain the initial diagnostic test for TB suspects. In most LICs, the prevalence of RMP resistance among new TB patients is very low; an Xpert MTB/RIF result indicating RMP resistance will thus always need confirmation by another test. In a population at high risk of RMP resistance (>15%), however, the positive predictive value for RMP resistance by Xpert MTB/RIF is high, and identification of RMP resistance is an excellent proxy for multidrug-resistant TB (MDR-TB). The assay should be widely used for this purpose if, and only if, excellent MDR-TB management is available, both for ethical reasons and to reduce the risk of extensively drug-resistant TB.

Original languageEnglish
Pages (from-to)1567-1571
Number of pages5
JournalInternational Journal of Tuberculosis and Lung Disease
Volume15
Issue number12
DOIs
Publication statusPublished - Dec 2011
Externally publishedYes

Fingerprint

Rifampin
Tuberculosis
Microscopy
Extensively Drug-Resistant Tuberculosis
Multidrug-Resistant Tuberculosis
Electricity
Proxy
Sputum
Routine Diagnostic Tests
Maintenance
Costs and Cost Analysis
Temperature
Research

Keywords

  • Diagnostics
  • GeneXpert
  • Low-income countries
  • Tuberculosis
  • Xpert® MTB/RIF

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Infectious Diseases

Cite this

Xpert® MTB/RIF for national tuberculosis programmes in low-income countries : When, where and how? / Trébucq, Arnaud; Enarson, D. A.; Chiang, C. Y.; Van Deun, A.; Harries, A. D.; Boillot, F.; Detjen, A.; Fujiwara, P. I.; Graham, S. M.; Monedero, I.; Rusen, I. D.; Rieder, H. L.

In: International Journal of Tuberculosis and Lung Disease, Vol. 15, No. 12, 12.2011, p. 1567-1571.

Research output: Contribution to journalArticle

Trébucq, A, Enarson, DA, Chiang, CY, Van Deun, A, Harries, AD, Boillot, F, Detjen, A, Fujiwara, PI, Graham, SM, Monedero, I, Rusen, ID & Rieder, HL 2011, 'Xpert® MTB/RIF for national tuberculosis programmes in low-income countries: When, where and how?', International Journal of Tuberculosis and Lung Disease, vol. 15, no. 12, pp. 1567-1571. https://doi.org/10.5588/ijtld.11.0392
Trébucq, Arnaud ; Enarson, D. A. ; Chiang, C. Y. ; Van Deun, A. ; Harries, A. D. ; Boillot, F. ; Detjen, A. ; Fujiwara, P. I. ; Graham, S. M. ; Monedero, I. ; Rusen, I. D. ; Rieder, H. L. / Xpert® MTB/RIF for national tuberculosis programmes in low-income countries : When, where and how?. In: International Journal of Tuberculosis and Lung Disease. 2011 ; Vol. 15, No. 12. pp. 1567-1571.
@article{4b861268e6914f3381c813586b206ac3,
title = "Xpert{\circledR} MTB/RIF for national tuberculosis programmes in low-income countries: When, where and how?",
abstract = "Xpert{\circledR} MTB/RIF offers new and important possibilities for the diagnosis of sputum smear-negative tuberculosis (TB) and/or rifampicin (RMP) resistance, and many are encouraging rapid and widespread implementation. This simple test can be implemented almost everywhere, and it provides results within a few hours. In low-income countries (LICs), however, its cost, environmental limitations (stable and regular electricity, adequate room temperature) and difficulties involved in supply and maintenance are major obstacles. While it may be suitable for major reference hospitals, operational research is needed to evaluate the test and its additional yield above high-quality smear microscopy and clinical algorithms before its use at the peripheral level. In the meantime, direct microscopy should remain the initial diagnostic test for TB suspects. In most LICs, the prevalence of RMP resistance among new TB patients is very low; an Xpert MTB/RIF result indicating RMP resistance will thus always need confirmation by another test. In a population at high risk of RMP resistance (>15{\%}), however, the positive predictive value for RMP resistance by Xpert MTB/RIF is high, and identification of RMP resistance is an excellent proxy for multidrug-resistant TB (MDR-TB). The assay should be widely used for this purpose if, and only if, excellent MDR-TB management is available, both for ethical reasons and to reduce the risk of extensively drug-resistant TB.",
keywords = "Diagnostics, GeneXpert, Low-income countries, Tuberculosis, Xpert{\circledR} MTB/RIF",
author = "Arnaud Tr{\'e}bucq and Enarson, {D. A.} and Chiang, {C. Y.} and {Van Deun}, A. and Harries, {A. D.} and F. Boillot and A. Detjen and Fujiwara, {P. I.} and Graham, {S. M.} and I. Monedero and Rusen, {I. D.} and Rieder, {H. L.}",
year = "2011",
month = "12",
doi = "10.5588/ijtld.11.0392",
language = "English",
volume = "15",
pages = "1567--1571",
journal = "International Journal of Tuberculosis and Lung Disease",
issn = "1027-3719",
publisher = "International Union against Tubercul. and Lung Dis.",
number = "12",

}

TY - JOUR

T1 - Xpert® MTB/RIF for national tuberculosis programmes in low-income countries

T2 - When, where and how?

AU - Trébucq, Arnaud

AU - Enarson, D. A.

AU - Chiang, C. Y.

AU - Van Deun, A.

AU - Harries, A. D.

AU - Boillot, F.

AU - Detjen, A.

AU - Fujiwara, P. I.

AU - Graham, S. M.

AU - Monedero, I.

AU - Rusen, I. D.

AU - Rieder, H. L.

PY - 2011/12

Y1 - 2011/12

N2 - Xpert® MTB/RIF offers new and important possibilities for the diagnosis of sputum smear-negative tuberculosis (TB) and/or rifampicin (RMP) resistance, and many are encouraging rapid and widespread implementation. This simple test can be implemented almost everywhere, and it provides results within a few hours. In low-income countries (LICs), however, its cost, environmental limitations (stable and regular electricity, adequate room temperature) and difficulties involved in supply and maintenance are major obstacles. While it may be suitable for major reference hospitals, operational research is needed to evaluate the test and its additional yield above high-quality smear microscopy and clinical algorithms before its use at the peripheral level. In the meantime, direct microscopy should remain the initial diagnostic test for TB suspects. In most LICs, the prevalence of RMP resistance among new TB patients is very low; an Xpert MTB/RIF result indicating RMP resistance will thus always need confirmation by another test. In a population at high risk of RMP resistance (>15%), however, the positive predictive value for RMP resistance by Xpert MTB/RIF is high, and identification of RMP resistance is an excellent proxy for multidrug-resistant TB (MDR-TB). The assay should be widely used for this purpose if, and only if, excellent MDR-TB management is available, both for ethical reasons and to reduce the risk of extensively drug-resistant TB.

AB - Xpert® MTB/RIF offers new and important possibilities for the diagnosis of sputum smear-negative tuberculosis (TB) and/or rifampicin (RMP) resistance, and many are encouraging rapid and widespread implementation. This simple test can be implemented almost everywhere, and it provides results within a few hours. In low-income countries (LICs), however, its cost, environmental limitations (stable and regular electricity, adequate room temperature) and difficulties involved in supply and maintenance are major obstacles. While it may be suitable for major reference hospitals, operational research is needed to evaluate the test and its additional yield above high-quality smear microscopy and clinical algorithms before its use at the peripheral level. In the meantime, direct microscopy should remain the initial diagnostic test for TB suspects. In most LICs, the prevalence of RMP resistance among new TB patients is very low; an Xpert MTB/RIF result indicating RMP resistance will thus always need confirmation by another test. In a population at high risk of RMP resistance (>15%), however, the positive predictive value for RMP resistance by Xpert MTB/RIF is high, and identification of RMP resistance is an excellent proxy for multidrug-resistant TB (MDR-TB). The assay should be widely used for this purpose if, and only if, excellent MDR-TB management is available, both for ethical reasons and to reduce the risk of extensively drug-resistant TB.

KW - Diagnostics

KW - GeneXpert

KW - Low-income countries

KW - Tuberculosis

KW - Xpert® MTB/RIF

UR - http://www.scopus.com/inward/record.url?scp=81455138225&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=81455138225&partnerID=8YFLogxK

U2 - 10.5588/ijtld.11.0392

DO - 10.5588/ijtld.11.0392

M3 - Article

VL - 15

SP - 1567

EP - 1571

JO - International Journal of Tuberculosis and Lung Disease

JF - International Journal of Tuberculosis and Lung Disease

SN - 1027-3719

IS - 12

ER -